FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Conroy, Thierry; Hammel, Pascal; Hebbar, Mohamed; Ben Abdelghani, Méher; C. Wei, Alice; Raoul, Jean‐Luc; Choné, Laurence; François, E.; Artru, Pascal; Biagi, James; Lecomte, Thierry; Assénat, Eric; Faroux, Roger; Ychou, Marc; Volet, Julien; Sauvanet, Alain; Breysacher, Gilles; Di Fiore, Frédéric; Cripps, C.; Kavan, Petr; Texereau, Patrick; Bouhier‐Leporrier, Karine; Khemissa-Akouz, Faiza; Legoux, Jean-Louis; Juzyna, Béata; Gourgou, Sophie; J. O’Callaghan, Christopher; Jouffroy-Zeller, Claire; Rat, Patrick; Malka, David; Castan, Florence; Bachet, Jean‐Baptiste

doi:10.1056/nejmoa1809775

Public

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Published in New England Journal of Medicine • Dec 19, 2018

Authors:

Thierry Conroy

Pascal Hammel

Mohamed Hebbar

Abstract

BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitab...

Subject

Gemcitabine

FOLFIRINOX

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!